日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Impact of tranexamic acid on postpartum hemorrhage in type 1 von Willebrand disease treated with recombinant VWF

氨甲环酸对接受重组血管性血友病因子治疗的1型血管性血友病患者产后出血的影响

期刊:Blood Advances
影响因子:7.1
doi:10.1182/bloodadvances.2025017046
Machin, Nicoletta C; Brooks, Maria M; Vehec, Deborah; Ivanco, Dana; Lawryk, Brandon; Seaman, Craig D; Xavier, Frederico; Shiva, Sruti; Verdoni, Angela; Ragni, Margaret V
发表日期：2025
文献求助 收藏

NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer

NSABP FB-10：一项评估ado-trastuzumab emtansine (T-DM1)联合neratinib治疗HER2阳性转移性乳腺癌女性患者的Ib/II期临床试验

期刊:Breast Cancer Research
影响因子:5.6
doi:10.1186/s13058-024-01823-8
Jacobs, Samuel A; Wang, Ying; Abraham, Jame; Feng, Huichen; Montero, Alberto J; Lipchik, Corey; Finnigan, Melanie; Jankowitz, Rachel C; Salkeni, Mohamad A; Maley, Sai K; Puhalla, Shannon L; Piette, Fanny; Quinn, Katie; Chang, Kyle; Nagy, Rebecca J; Allegra, Carmen J; Vehec, Kelly; Wolmark, Norman; Lucas, Peter C; Srinivasan, Ashok; Pogue-Geile, Katherine L
HER2
肿瘤
肿瘤免疫
乳腺癌
发表日期：2024
文献求助 收藏

Correction: NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer

更正：NSABP FB-10：一项评估ado-trastuzumab emtansine (T-DM1)联合neratinib治疗HER2阳性转移性乳腺癌女性患者的Ib/II期临床试验

期刊:Breast Cancer Research
影响因子:5.6
doi:10.1186/s13058-024-01833-6
Jacobs, Samuel A; Wang, Ying; Abraham, Jame; Feng, Huichen; Montero, Alberto J; Lipchik, Corey; Finnigan, Melanie; Jankowitz, Rachel C; Salkeni, Mohamad A; Maley, Sai K; Puhalla, Shannon L; Piette, Fanny; Quinn, Katie; Chang, Kyle; Nagy, Rebecca J; Allegra, Carmen J; Vehec, Kelly; Wolmark, Norman; Lucas, Peter C; Srinivasan, Ashok; Pogue-Geile, Katherine L
HER2
肿瘤
肿瘤免疫
乳腺癌
发表日期：2024
文献求助 收藏

Recombinant von Willebrand factor and tranexamic acid for heavy menstrual bleeding in patients with mild and moderate von Willebrand disease in the USA (VWDMin): a phase 3, open-label, randomised, crossover trial

在美国，一项针对轻度至中度血管性血友病（VWDMin）患者，采用重组血管性血友病因子和氨甲环酸治疗月经过多的3期开放标签随机交叉试验

期刊:Lancet Haematology
影响因子:17.7
doi:10.1016/S2352-3026(23)00119-9
Ragni, Margaret V; Rothenberger, Scott D; Feldman, Robert; Nance, Danielle; Leavitt, Andrew D; Malec, Lynn; Kulkarni, Roshni; Sidonio, Robert Jr; Kraut, Eric; Lasky, Joseph; Pruthi, Rajiv; Angelini, Dana; Philipp, Claire; Hwang, Nina; Wheeler, Allison P; Seaman, Craig; Machin, Nicoletta; Xavier, Frederico; Meyer, Michael; Bellissimo, Daniel; Humphreys, Gregory; Smith, Kenneth J; Merricks, Elizabeth P; Nichols, Timothy C; Ivanco, Dana; Vehec, Deborah; Koerbel, Glory; Althouse, Andrew D
发表日期：2023
文献求助 收藏